APP and Alzheimer disease: The 3,4-dihydroxybenzoic acid reduced Aβ levels in the hippocampus and cerebral cortex of amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic Alzheimer’s disease (AD) model mice [132].